Innovative Pipelines From Avanir and Cyclacel Pharmaceuticals Gain Momentum
The Bedford Report Provides Equity Research on Avanir Pharmaceuticals & Cyclacel Pharmaceuticals
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 10/10/11 -- The biotech industry is generating significant investor interest this year as an influx of new and lucrative therapies work their way towards regulatory approval. Although younger, unprofitable firms are having difficulty securing funding, reports suggest biotech companies with promising pipelines should be able to secure necessary capital. The Bedford Report examines the outlook for companies in the biotechnology industry and provides equity research on Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) and Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC). Access to the full company reports can be found at:
According to a recent report from Ernst & Young, US biotech companies raised $25 billion last year -- a 15 percent jump over the previous year and the highest amount since 2007. Of concern is that more than 82 percent of that funding went to 20 percent of the companies. Younger, unprofitable companies in the US that depend on funding from venture capital firms, stock sales and partnerships saw available capital decline 21 percent in 2010.
The Bedford Report releases investment research on the Biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. Avanir began selling Nuedexta in February. The drug is approved as a treatment for pseudobulbar affect, a condition that involves involuntary emotional outbursts like laughing or crying. It is associated with brain disease or injury.
Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 3 development for the front-line treatment of acute myeloid leukemia in the elderly and Phase 2 studies for myelodysplastic syndromes and lung cancer.
The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: .
Contact:
The Bedford Report
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.10.2011 - 12:16 Uhr
Sprache: Deutsch
News-ID 74187
Anzahl Zeichen: 5525
contact information:
Town:
NEW YORK, NY
Kategorie:
Insurance
Diese Pressemitteilung wurde bisher 207 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Innovative Pipelines From Avanir and Cyclacel Pharmaceuticals Gain Momentum"
steht unter der journalistisch-redaktionellen Verantwortung von
The Bedford Report (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
